Dupixent
FDA approves Dupixent for chronic rhinosinusitis with nasal polyposis
June 27, 2019Sales and Marketing Dupixent, FDA, Sanofi, US, pharma, rhinosinusitis
Regeneron Pharmaceuticals and Sanofi have revealed that their dual IL-4 and IL-13 inhibitor Dupixent (dupilumab) has secured FDA approval in …
Sanofi’s Dupixent approved in Europe for severe asthma maintenance
May 9, 2019Sales and Marketing Dupixent, EU, Europe, Sanofi, asthma, pharma
Sanofi has revealed that its interleukin-4 and interleukin-13 (IL-4 and IL-13) inhibitor Dupixent (dupilumab) has been awarded marketing approval by …
FDA expands Dupixent indication to include moderate-to-severe atopic dermatitis in adolescent patients
March 12, 2019Manufacturing and Production, Sales and Marketing Dupixent, Regeneron, Sanofi, pharma
Partners Sanofi and Regeneron have both revealed that their jointly developed drug Dupixent (dupilumab) has been authorised by the FDA …
Sanofi’s Dupixent improves symptoms in rhinosinusitis with nasal polyps at Phase 3
February 27, 2019Research and Development Dupixent, Sanofi, pharma, rhinosinusitis
New data has been released on Sanofi’s Dupixent (dupilumab), derived from two Phase 3 trials, illustrating the drug’s efficacy In …
Sanofi’s Dupixent improves symptoms for adolescent atopic dermatitis patients
September 17, 2018Research and Development, Sales and Marketing Dupixent, EADV 2018, Sanofi, atopic dermatitis, pharma
Sanofi’s Dupixent (dupilumab) has made a strong showing as a monotherapy at Phase 3 in the treatment of moderate-to-severe atopic …
NICE rejects Dupixent for atopic dermatitis on cost grounds, Sanofi responds
April 4, 2018Research and Development, Sales and Marketing Dupixent, NICE, Sanofi, atopic dermatitis, eczema, pharma
UK drug watchdog NCIE has issued draft guidance rejecting the routine use of Sanofi’s Dupixent (dupilumab) for the treatment of …
Sanofi and Regeneron’s projected blockbuster gains EU approval
September 28, 2017Sales and Marketing Dupixent, Regeneron, Sanofi, biotech, drugs, pharma, pharmaceutical
Sanofi and Regeneron have big hopes for their treatment Dupixent, and it has taken an important step towards reaching the …
Sanofi/Regeneron new asthma data bolstered by potential indications
September 13, 2017Research and Development Dupixent, Regeneron, Sanofi, biotech, drugs, pharma, pharmaceutical
Sanofi and Regeneron’s Dupixent is predicted to grow to be one of the largest selling drugs in the industry but …
FDA approves first-ever atopic dermatitis biologic treatment
March 31, 2017Medical Communications, Sales and Marketing Dupixent, Regeneron, Sanofi, atopic dermatitis, biologic
Sanofi and Regeneron’s Dupixent (dupilumab) has become the first biologic medicine to be approved by the FDA for the treatment …
Breakthrough eczema drug given FDA approval
March 29, 2017Research and Development, Sales and Marketing Dupixent, Regeneron, Sanofi
Regeneron and Sanofi have received approval for its eczema treatment, Dupixent, by the FDA. The treatment will be the first …
